ZD1839 and Cisplatin Alone or in Combination for Treatment of a Nasopharyngeal Carcinoma Cell Line and Xenografts |
Gu, Wei-Guang
(Department of Medical Oncology, Nanhai District People's Hospital)
Huang, Yan (Department of Medical Oncology, Sun Yat-Sen University Cancer Center) Yuan, Zhong-Yu (Department of Medical Oncology, Sun Yat-Sen University Cancer Center) Peng, Rou-Jun (Department of Medical Oncology, Sun Yat-Sen University Cancer Center) Luo, Hai-Tao (Department of Medical Oncology, Nanhai District People's Hospital) He, Zhi-Ren (Department of Medical Oncology, Nanhai District People's Hospital) Wang, Shu-Sen (Department of Medical Oncology, Sun Yat-Sen University Cancer Center) |
1 | Adelstein DJ, Rodriguez CP, Rybicki LA, et al (2012). A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs, 30, 1684-9. DOI ScienceOn |
2 | Barker AJ, Gibson KH, Grundy W, et al (2001). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett, 11, 1911-4. DOI ScienceOn |
3 | Chan SL, Ma BB (2012). Novel systemic therapeutic for nasopharyngeal carcinoma. Expert Opin Ther Targets, 16, S63-8. DOI ScienceOn |
4 | Chua DT, Wei WI, Wong MP, et al (2008). Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck, 30, 863-7. DOI ScienceOn |
5 | Ciardiello F, Caputo R, Bianco R, et al (2000). Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res, 6, 2053-63. |
6 | Ciardiello F, Caputo R, Bianco R, et al (2001). Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 7, 1459-65. |
7 | Ciardiello F, Tortora G (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7, 2958-70. |
8 | Cohen MH, Williams GA, Sridhara R, et al (2003). FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist, 8, 303-6. DOI ScienceOn |
9 | Engebraaten O, Edvardsen H, Løkkevik E, et al (2012). Gefitinib in combination with weekly docetaxel in patients with metastatic breast cancer caused unexpected toxicity: results from a randomized phase II clinical trial. ISRN Oncol, 2012, 176789. |
10 | Gejyo F, Chang JL, Burgi W, et al (1983) Characterization of the B-chain of human plasma alpha 2HS-glycoprotein. The complete amino acid sequence and primary structure of its heteroglycan. J Biol Chem, 258, 4966-71. |
11 | Gregoire V, Hamoir M, Chen C, et al (2011). Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol, 100, 62-9. DOI ScienceOn |
12 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
13 | Joensuu G, Joensuu T, Nupponen N, et al (2012). A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy. Acta Oncol, 51, 130-3. DOI ScienceOn |
14 | Kindler HL, Friberg G, Skoog L, et al (2005). Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol, 28, 340-4. DOI ScienceOn |
15 | Lee AW, Lin JC, Ng WT (2012). Current management of nasopharyngeal cancer. Semin Radiat Oncol, 22, 233-44. DOI ScienceOn |
16 | Lewis CM, Glisson BS, Feng L, et al (2012). A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res, 18, 1435-46. DOI ScienceOn |
17 | Ma BB, Kam MK, Leung SF, et al (2012). A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol, 23, 1287-92. DOI ScienceOn |
18 | Ranson M (2002). ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist, 7, 16-24. |
19 | Sirotnak FM (2003). Studies with ZD1839 in preclinical models. Semin Oncol, 30, 12-20. |
20 | Wakeling AE, Guy SP, Woodburn JR, et al (2002). ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 62, 5749-54. |
21 | Woodburn J, Kendrew J, Fennell M, et al (2000). ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc Am Assoc Cancer Res, 41, 402. |
22 | You B, Le Tourneau C, Chen EX, et al (2012). A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol, 35, 255-60. DOI |
![]() |